+44 20 8123 2220
info@marketpublishers.com

Health Technology Assessment (HTA): a European perspective

https://marketpublishers.com/r/H6F3E519F6BEN.html
Date: October 2011
Pages: 48
Price: US$ 995.00 (Single User License)
ID: H6F3E519F6BEN

Abstracts

The bottom line: For payers facing tough financial crunches across Europe, Health Technology Assessment (HTA) is becoming increasingly important. Not only is HTA influencing reimbursement, it is having an impact on price and market access.

And it’s not surprising. With greater scrutiny over the clinical and financial value of drugs, medical devices and procedures, HTA is increasingly being accepted around the world. The European situation is somewhat different: existing across multiple borders, the ‘Europeanisation’ agenda of HTA has sparked debates about European-wide standards, the possibility of a single agency governing HTA and the need for formalized cooperation.

Scope

In Health Technology Assessment (HTA): a European perspective, FirstWord examines the current role of HTA in Europe, from its impact on reimbursement and pricing to market access. The report focuses on the experiences of five European nations, reviewing the history of HTA and the key agencies in each. Written by an expert health economist and with insight from experts from NICE, EUnetHTA , the EMA and leading pharmaceutical companies, the report reveals the problems, pitfalls and—most importantly—the potential of a harmonized approach to HTA in Europe.

Highlights

Detailed examination of the role of HTA in European pricing, reimbursement and market access

+44 20 8123 2220
info@marketpublishers.com

An overview of the role of HTA in Germany, France, Italy, Spain and the UK

Country-by-country breakdown of key agencies

Expert insight into the ‘Europeanisation’ of HTA and its key challenges

Review of the potential and pitfalls

Purchase Reasons

Full overview the role of HTA in Europe

Insights from experts in the European Medicines Agency, the National Institute for Health and Clinical Excellence and leading pharmaceutical companies

Comprehensive references to key literature

Key Questions Asked

What role does HTA play in pricing, reimbursement and market access?

What is the current state of play with HTA across Europe?

What changes are happening in HTA and what is their impact?

Does one size fit all in terms of transferability and adaptability?

What are the pitfalls, problems and potential of HTA in Europe?

Who Should Read This Report

Market Access directors & managers

Health Economics professionals

+44 20 8123 2220
info@marketpublishers.com

Pharmacoeconomics professionals

Health Outcomes / Outcomes Research professionals

Health Technology Assessment professionals

Health Policy professionals

Pricing & Reimbursement teams

Government and regulatory affairs analysts

Government and regulatory affairs analysts

Key quotes

“HTA is not the only game in town.”
– Keiron Sparrowhawk of PriceSpective

“There is the situation of the UK, where the whole pricing and reimbursement system is experiencing a change. The idea is to integrate the HTA system, particularly NICE, into an overarching pricing system more explicitly, much more explicitly than at present.”
– Gunter Harms, Market Access & Public Affairs Director, Shire Human Genetic Therapies

“There is a lot of difference in the governance across Europe, which ultimately leads to quality of HTA. An important aspect is of course the independence of the assessment from the appraisal and ultimately the decision on a certain price. That's very, very different country by country and region by region.”
– Ansgar Hebborn, Global Head, Payer and HTA Programme Policy, Roche

Expert Views

Alicia Granados, MD. Senior Director Global HTA Strategy, GMA Genzyme

Andrea Rappagliosi, Vice President European Government Affairs & Head of Brussels Office, GlaxoSmithKline

+44 20 8123 2220
info@marketpublishers.com

Andrew Hobbs, Managing Director, Pope Woodhead and Associates Limited

Ansgar Hebborn, Global Head, Payer and HTA Programme Policy, Roche

Brian Lovatt, Chief Executive Officer, Vision Healthcare

Clare McGrath, Senior Director HTA Policy, Pfizer

David Grainger, Global Public Policy Director, Lilly

Finn Borlum Kristensen, Director, EUnetHTA Secretariat and Chair, EUnetHTA Executive Committee

Gunter Harms, Market Access & Public Affairs Director, Shire Human Genetic Therapies

Hans Georg Eichler, Senior Medical Officer, European Medicines Agency

Kalipso Chalkidou, Director of International Division, National Institute for Health and Clinical Excellence

Karen Facey, Evidence based health policy consultant and non-executive Director at NHS Health Scotland, and Chair of the HTAi Interest Group for Patient/Citizen Involvement in HTA

Mel Walker, Senior Director Value Expert Engagement & Collaborations, GlaxoSmithKline

Rito Bergemann, Medical Director, HTA Strategy Global HEOR, Abbott

Steven Flostrand, Principal, Pricing & Market Access, IMS Health

Ulf Staginnus, Head of Pricing & Health Economics Europe, Novartis and author of www.healtheconomicsblog.com

Vivek Muthu, Chief Executive, Bazian

Keiron Sparrowhawk, Partner, PriceSpective

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

POTENTIALS AND PITFALLS OF EUROPEANISATION OF HTA

CONCLUSIONS

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Health Technology Assessment (HTA): a European perspective

Product link: https://marketpublishers.com/r/H6F3E519F6BEN.html

Price: US$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/H6F3E519F6BEN.html